TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis
about
Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran populationComparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritisIdentification of risk factors for elevated transaminases in methotrexate users through an electronic health record.Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review.Prevalence and microbiological characteristics of clinically infected foot-ulcers in patients with rheumatoid arthritis: a retrospective exploratory studyDrug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis.Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.Increased risk of pneumonia among patients with inflammatory bowel disease.A Fatal Case of Relapsing Pneumonia Caused by Legionella pneumophila in a Patient with Rheumatoid Arthritis After Two Injections of Adalimumab.Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis."Serious skin & soft tissue infections in rheumatoid arthritis patients taking anti-tumor necrosis factor alpha drugs: a nested case-control study".Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature.Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature.Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis.The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.Infectious complications in juvenile idiopathic arthritis.Challenges and approaches for the development of safer immunomodulatory biologics.Rheumatoid arthritis in the elderly in the era of tight control.Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Safety issues and concerns of new immunomodulators in rheumatology.Staphylococcus aureus sepsis in rheumatoid arthritis.Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy.Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance.Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry.Significant Associations of Neurological Complications of Herpes Zoster With Stroke in Rheumatoid Arthritis Patients.Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis.Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications.Monoarthritis in a 28-Year-Old Man With Juvenile Idiopathic Arthritis.Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry.Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients.Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis.
P2860
Q33667897-A384AEDB-D088-4A4D-A07C-3E3A15C6C09BQ33778719-A766C7E2-AA1E-4527-8BEF-614F162C6E41Q33841390-FA3CDC24-E29E-4403-A7B2-AA231EB36477Q33955217-8829CFB5-54A6-4D71-975E-674EF811B9DEQ35705082-E78B7D16-88C9-4996-B50A-EC1086F00C92Q35957200-52F69F74-56BF-4563-A413-9A5CE02688C2Q36099620-04456B4B-1C34-405E-B70C-10AD80916985Q36191250-FA302015-2BC8-4B6E-B4CA-5EB50FEDC27AQ36219145-2F806426-667C-4D8F-9BDF-D834DD64D8FFQ36981074-213F231F-D5BA-41E2-82B0-7CADB0040F37Q37189376-EFCD18EF-85A6-4FB2-BC25-E313C63384F0Q37196596-D02E6924-E511-4158-AE88-518F3FAB8B63Q37343166-B3403EBF-1D3C-4300-B8F5-D609F556B1A0Q37358271-F373214A-A0ED-4701-BC97-81A2E3F70DA3Q37463702-E7490834-52D4-48C0-84D6-4F12890194A7Q37576833-6BBCC2E6-DA1E-4553-850A-E7BB3760A0C8Q37729543-56EEBE99-0CFE-435B-A3A0-A07C7C714002Q38063474-1D0D2214-2F83-4656-BF58-BC6F46112046Q38093095-FC0B005A-9C65-4D8C-94BA-044D1AB5DC96Q38093772-FF516CF8-60F9-44D4-A22D-A96650A579F2Q38150731-848C8968-0EA4-4CC1-B181-2CDA19B61EF8Q38176745-E8B3D136-CBC8-4472-981A-FD2EDFD05D32Q38292111-016C929C-4682-4FD2-AC4C-8C1E0B22145AQ38372766-F5575B98-A2D6-4C21-BA86-34E9CB713B93Q38611360-24149A5D-0B56-452E-8C05-BDC4E18A08C1Q38827889-C647E420-167A-434E-8671-15357DD8BE5CQ40047193-AE75AC17-0B12-4482-A6D8-C203DFD944BDQ40116120-B4B592D2-4A65-4265-B71E-59ED5F48B2B5Q40242247-C2CACE79-8883-499B-8333-1A34C5B9EC0BQ40553708-A0CC5252-0286-4A47-89C2-22F2EF02F72DQ41363297-EF0556A8-37CD-4C8B-8D8E-1BCD1A2DAB04Q41709276-9996A7B4-BAA2-4A11-B0E2-2A6CE7118B59Q42215038-3B81E658-9A95-48A3-B508-051C596EAF61Q44518151-7C95B915-768D-4DDE-B15E-4E368233AC50Q47625115-F1581FD2-6534-40C6-9625-B3B36F900A63
P2860
TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
TNF-α antagonist use and risk ...... rans with rheumatoid arthritis
@ast
TNF-α antagonist use and risk ...... rans with rheumatoid arthritis
@en
TNF-α antagonist use and risk ...... rans with rheumatoid arthritis
@nl
type
label
TNF-α antagonist use and risk ...... rans with rheumatoid arthritis
@ast
TNF-α antagonist use and risk ...... rans with rheumatoid arthritis
@en
TNF-α antagonist use and risk ...... rans with rheumatoid arthritis
@nl
prefLabel
TNF-α antagonist use and risk ...... rans with rheumatoid arthritis
@ast
TNF-α antagonist use and risk ...... rans with rheumatoid arthritis
@en
TNF-α antagonist use and risk ...... rans with rheumatoid arthritis
@nl
P2093
P2860
P921
P1433
P1476
TNF-α antagonist use and risk ...... rans with rheumatoid arthritis
@en
P2093
Angelique L Zeringue
Jay R McDonald
Jeffrey R Curtis
Liron Caplan
Prabha Ranganathan
Seth A Eisen
P2860
P304
P356
10.1097/MD.0B013E318211106A
P407
P577
2011-03-01T00:00:00Z